Shots:
Metsera announced entering into an amended merger agreement with Pfizer to acquire Metsera for up to $86.25 per share, including $65.60 in cash and a contingent value right of up to $20.65
Metsera’s Board of Directors noted that the U.S. Federal Trade Commission had raised potential antitrust concerns regarding Novo Nordisk’s proposed structure
After…
Shots:
Metsera has declared Novo Nordisk’s unsolicited ~$9B acquisition proposal, valuing shares up to $77.75, as a “Superior Company Proposal” than its existing Pfizer Merger Agreement
The 2-step proposal incl. an initial $56.5/share cash payment & issuance of non-voting preferred stock for 50% of Metsera’s share capital, followed by a CVR of ~$21.25/share in cash…
Shots:
Welcome to the October edition of Know Your Investor, spotlighting leading investors shaping the future of healthcare and life sciences
This month, we feature Google Ventures (GV), the venture capital arm of Alphabet. GV actively invests across seed to growth-stage companies, spanning sectors such as software, internet, healthcare, life sciences, and artificial intelligence
For…
Shots:
Pfizer has entered into a definitive agreement to acquire Metsera, expanding to obesity & cardiometabolic market
As per the deal, Metsera will receive $47.5/share, representing an enterprise value of ~$4.9B, plus a non-transferable CVR of ~$22.50/share tied to milestones: $5 on P-III start of MET-097i + MET-233i, $7 on FDA approval for MET-097i monotx.,…
Shots:
Welcome to the 2025 edition of Know Your Investor, highlighting top venture capital firms driving healthcare innovation
This edition features Deep Track Capital, a firm dedicated to investing in life sciences companies that are advancing innovations to improve public health
In 2024, Deep Track Capital invested approximately $4.35B across six funding rounds, adding 32…
Shots:
Welcome to the 2025 series of Know Your Investor, featuring top venture capital firms focused on healthcare.
This edition highlights Janus Henderson Group Plc, a global investment firm managing approximately $378.7B in assets across Equities, Fixed Income, Multi-Asset, and Alternatives.
In 2024, the firm invested $5.36B across six funding rounds, adding 39 healthcare and…

